NOS3 and metabolic syndrome: Especially, FPE‐FGE (3:7), which includes a combination of various glycosides or aglycones, such as daidzein and genistein, additively or synergistically attenuated the menopausal dyslipidemia by upregulating eNOS‐NO‐cGMP signaling pathway.